Company intelligence / Profile preview

Taiwan Sunpan Biotechnology Development Co., Ltd.

Taoyuan City, Taoyuan City, Taiwancdek.pharmacy.purdue.edu ↗

Ownership: Private
Development stage: Phase 1

Overview

TSB’s lead candidate, TSB-9-W1 (“IDS”), is a botanical small molecule drug developed for metastatic colorectal cancer. It has completed a Phase 1 trial to determine maximum tolerated dose and evaluate safety, efficacy, and pharmacokinetics in pre-treated mCRC patients. The company holds patents for this compound in the US, Japan, and Taiwan. The R&D lab is ISO/IEC 17025 certified by the Taiwan Accreditation Foundation.[1][3] No published results from later-stage trials are available.

Therapeutic areas: Oncology
Modalities: Botanical drugsSmall molecules
Industry: Biotech

Drug pipeline

2 assets

TSB-9-W1

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Taiwan Sunpan Biotechnology Development Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Taiwan Sunpan Biotechnology Development Co., Ltd..

Explore the full profile